Disc Medicine 近日公布了与美国食品药品监督管理局（FDA）就其在研药物 bitopertin 用于治疗红细胞生成性原卟啉症（EPP）所举行的 A 类会议的最新进展。此次会议旨在讨论该药物的开发计划与相关数据。
Disc Medicine 近日公布了与美国食品药品监督管理局（FDA）就其在研药物 bitopertin 用于治疗红细胞生成性原卟啉症（EPP）所举行的 A 类会议的最新进展。此次会议旨在讨论该药物的开发计划与相关数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.